Atria Investments LLC Vertex Pharmaceuticals Inc Transaction History

Atria Investments LLC

  • $7.56 Billion
  • Q3 2024

A detailed history of Atria Investments LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Atria Investments LLC holds 20,125 shares of VRTX stock, worth $9.35 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
20,125
Previous 21,689 7.21%
Holding current value
$9.35 Million
Previous $10.2 Million 7.94%
% of portfolio
0.12%
Previous 0.14%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024
SELL
$460.0 - $505.78 $719,440 - $791,039
-1,564 Reduced 7.21%
20,125 $9.36 Million
Q2 2024

Aug 13, 2024
BUY
$392.81 - $485.53 $458,802 - $567,099
1,168 Added 5.69%
21,689 $10.2 Million
Q1 2024

May 21, 2024
SELL
$407.69 - $446.08 $345,313 - $377,829
-847 Reduced 3.96%
20,521 $8.58 Million
Q4 2023

Feb 14, 2024
SELL
$343.0 - $410.68 $350,889 - $420,125
-1,023 Reduced 4.57%
21,368 $8.69 Million
Q3 2023

Nov 07, 2023
SELL
$338.18 - $362.46 $4,734 - $5,074
-14 Reduced 0.06%
22,391 $7.79 Million
Q2 2023

Aug 04, 2023
BUY
$314.42 - $351.91 $340,202 - $380,766
1,082 Added 5.07%
22,405 $7.88 Million
Q1 2023

May 10, 2023
SELL
$283.23 - $323.1 $1.79 Million - $2.04 Million
-6,321 Reduced 22.87%
21,323 $6.72 Million
Q4 2022

Jan 31, 2023
SELL
$285.76 - $321.48 $30,004 - $33,755
-105 Reduced 0.38%
27,644 $7.98 Million
Q3 2022

Nov 01, 2022
BUY
$273.83 - $305.53 $820,668 - $915,673
2,997 Added 12.11%
27,749 $8.03 Million
Q2 2022

Aug 11, 2022
SELL
$234.96 - $292.55 $1.12 Million - $1.39 Million
-4,758 Reduced 16.12%
24,752 $6.98 Million
Q1 2022

May 02, 2022
BUY
$221.42 - $260.97 $639,903 - $754,203
2,890 Added 10.86%
29,510 $7.7 Million
Q4 2021

Feb 04, 2022
BUY
$177.01 - $223.45 $253,655 - $320,203
1,433 Added 5.69%
26,620 $5.85 Million
Q3 2021

Nov 16, 2021
BUY
$181.39 - $202.99 $2.67 Million - $2.99 Million
14,721 Added 140.66%
25,187 $4.57 Million
Q2 2021

Aug 10, 2021
BUY
$187.49 - $221.1 $420,540 - $495,927
2,243 Added 27.28%
10,466 $2.11 Million
Q1 2021

May 11, 2021
SELL
$207.02 - $241.31 $367,046 - $427,842
-1,773 Reduced 17.74%
8,223 $1.77 Million
Q4 2020

Feb 12, 2021
BUY
$207.01 - $276.09 $125,862 - $167,862
608 Added 6.48%
9,996 $2.36 Million
Q3 2020

Nov 05, 2020
SELL
$255.65 - $303.1 $3.34 Million - $3.96 Million
-13,072 Reduced 58.2%
9,388 $2.56 Million
Q2 2020

Sep 22, 2020
BUY
$225.48 - $295.8 $3.42 Million - $4.49 Million
15,172 Added 208.18%
22,460 $6.52 Million
Q1 2020

May 15, 2020
BUY
$199.77 - $247.81 $79,708 - $98,876
399 Added 5.79%
7,288 $1.73 Million
Q4 2019

Feb 11, 2020
BUY
$166.71 - $223.91 $654,003 - $878,398
3,923 Added 132.27%
6,889 $1.51 Million
Q3 2019

Nov 14, 2019
SELL
$166.23 - $187.09 $81,286 - $91,487
-489 Reduced 14.15%
2,966 $502,000
Q2 2019

Aug 26, 2019
BUY
$164.61 - $190.37 $568,727 - $657,728
3,455 New
3,455 $625,000
Q2 2019

Aug 09, 2019
SELL
$164.61 - $190.37 $864,696 - $1 Million
-5,253 Closed
0 $0
Q1 2019

May 15, 2019
SELL
$163.73 - $194.7 $33,400 - $39,718
-204 Reduced 3.74%
5,253 $966,000
Q4 2018

Feb 12, 2019
SELL
$151.91 - $192.21 $94,943 - $120,131
-625 Reduced 10.28%
5,457 $904,000
Q3 2018

Oct 09, 2018
BUY
$167.73 - $192.74 $363,638 - $417,860
2,168 Added 55.39%
6,082 $1.17 Million
Q2 2018

Jul 13, 2018
BUY
$145.72 - $169.96 $9,471 - $11,047
65 Added 1.69%
3,914 $665,000
Q1 2018

Apr 30, 2018
SELL
$151.6 - $177.13 $138,865 - $162,251
-916 Reduced 19.22%
3,849 $627,000
Q4 2017

Jan 16, 2018
BUY
$137.28 - $155.55 $48,048 - $54,442
350 Added 7.93%
4,765 $714,000
Q3 2017

Oct 12, 2017
BUY
$148.13 - $162.24 $653,993 - $716,289
4,415
4,415 $671,000

Others Institutions Holding VRTX

# of Institutions
1,724
Shares Held
222M
Call Options Held
1.58M
Put Options Held
1.36M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Atria Investments LLC Portfolio

Follow Atria Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atria Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atria Investments LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email